Cargando…

Editorial: Therapeutic strategies for drug-induced liver injury: Review of the current literature

Detalles Bibliográficos
Autores principales:	Robles-Díaz, Mercedes, Sanabria-Cabrera, Judith, Björnsson, Einar S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731123/ https://www.ncbi.nlm.nih.gov/pubmed/36506512 http://dx.doi.org/10.3389/fphar.2022.1094732

Ejemplares similares

Role of Corticosteroids in Drug-Induced Liver Injury. A Systematic Review
por: Björnsson, Einar S., et al.
Publicado: (2022)

Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A Systematic Review
por: Robles-Díaz, Mercedes, et al.
Publicado: (2021)

N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review
por: Sanabria-Cabrera, Judith, et al.
Publicado: (2022)

Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review
por: Li, Meng, et al.
Publicado: (2022)

Clinical management of patients with drug‐induced liver injury (DILI)
por: Björnsson, Einar S.
Publicado: (2021)

Editorial: Inflammation and aging in chronic and degenerative diseases: Current and future therapeutic strategies
por: Falzone, Luca, et al.
Publicado: (2023)

Editorial: Current Aspects in Chemopreventive Strategies
por: Tuli, Hardeep Singh, et al.
Publicado: (2021)

N-Acetylcysteine for Preventing Acetaminophen-Induced Liver Injury: A Comprehensive Review
por: Licata, Anna, et al.
Publicado: (2022)

Biologic and Checkpoint Inhibitor‐Induced Liver Injury: A Systematic Literature Review
por: Shah, Parth, et al.
Publicado: (2020)

Editorial: Biologically active products as therapeutic options for the treatment of cardiovascular diseases related to liver injury
por: Gasparotto Junior, Arquimedes, et al.
Publicado: (2022)

Editorial: Current Aspects in Chemopreventive Strategies, Volume II
por: Tuli, Hardeep Singh, et al.
Publicado: (2022)

Editorial: Drug Repositioning: Current Advances and Future Perspectives
por: Nishimura, Yuhei, et al.
Publicado: (2018)

Editorial: Therapeutic Drug Monitoring in Solid Organ Transplantation
por: Staatz, Christine E., et al.
Publicado: (2021)

Editorial: Epigenetic drugs and therapeutic resistance for epithelial malignancies
por: Tao, Fangfang, et al.
Publicado: (2023)

Editorial: Phytochemicals in cancer prevention and therapeutics: Current advancement and future perspective
por: Pore, Subrata Kumar, et al.
Publicado: (2023)

Editorial: Matricellular Receptors As Potential Targets in Anti-Cancer Therapeutic Strategies
por: Emonard, Hervé, et al.
Publicado: (2016)

Editorial: Antimycobacterial drug discovery: Molecular therapeutics and target identification
por: Gunosewoyo, Hendra, et al.
Publicado: (2022)

Editorial: Novel therapeutic target and drug discovery for neurological diseases
por: Zhao, Kaiyue, et al.
Publicado: (2022)

Editorial: Novel therapeutic approaches to target drug resistant tumors
por: Riganti, Chiara, et al.
Publicado: (2023)

Editorial: New drugs, approaches, and strategies to combat antimicrobial resistance
por: Singh, Chandra Kant, et al.
Publicado: (2023)

Current Strategies and Applications for Precision Drug Design
por: Wang, Chen, et al.
Publicado: (2018)

Editorial: Novel Therapeutic Target and Drug Development in Neurovascular Retinal Diseases
por: Shao, Zhuo, et al.
Publicado: (2021)

Editorial: Advanced chemical and material tools to enhance the therapeutic effect of drugs
por: Ihsan, Ayesha, et al.
Publicado: (2023)

Editorial: Ethnopharmacological Strategies for Drug Discovery Against African Neglected Diseases
por: Igoli, John O., et al.
Publicado: (2022)

Editorial: Drug-ability strategies for potential antimycobacterial candidate: opportunities and challenges
por: Swain, Shasank Sekhar, et al.
Publicado: (2023)

Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders
por: Shah, Sweta, et al.
Publicado: (2021)

A new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry
por: Björnsson, Einar S., et al.
Publicado: (2022)

Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease
por: Fu, Yajie, et al.
Publicado: (2022)

Editorial: Therapeutic potential of natural products-based drugs in regulation of lipid metabolism
por: Rašković, Aleksandar, et al.
Publicado: (2023)

Editorial: Antimycobacterial drug discovery: molecular therapeutics and target identification, Volume II
por: Gunosewoyo, Hendra, et al.
Publicado: (2023)

Editorial: Advances in non-alcoholic fatty liver disease therapeutics: Pathogenic mechanisms and targets
por: Blas-García, Ana, et al.
Publicado: (2022)

Current Molecular Therapeutic Agents and Drug Candidates for Mycobacterium abscessus
por: Quang, Nguyen Thanh, et al.
Publicado: (2021)

Editorial: Perspectives of Antiarrhythmic Drug Therapy: Disappointing Past, Current Efforts, and Faint Hopes
por: Nánási, Péter P., et al.
Publicado: (2020)

Therapeutic strategies for preventing skeletal muscle fibrosis after injury
por: Garg, Koyal, et al.
Publicado: (2015)

Editorial: Kappa opioid receptors revealed: Disentangling the pharmacology to open up new therapeutic strategies
por: Walwyn, Wendy Margaret, et al.
Publicado: (2022)

Molecular Mechanisms and Potential New Therapeutic Drugs for Liver Fibrosis
por: Wang, Fa-Da, et al.
Publicado: (2022)

Research Progress of Pharmacogenomics in Drug-Induced Liver Injury
por: Shao, Qihui, et al.
Publicado: (2021)

Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors
por: Raschi, Emanuel, et al.
Publicado: (2019)

Editorial: Therapeutic potential of plant-derived metabolites in spinal or sciatic injury-induced neuropathic pain
por: Khan, Abdul Waheed, et al.
Publicado: (2023)

Editorial: Drug-drug interactions in pharmacology
por: Pichini, Simona, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iiii1d4mj413uotv1v8a2q5h86